Circulating tumor DNA (ctDNA) as a pan-cancer screening test: is it finally on the horizon?

What is it about?

Most biomarkers currently available are of little value in screening for early cancer. Although PSA is widely used in screening for prostate cancer, it can miss some cancers. Furthermore, high levels can also be found in patients with benign prostate disease. One of the most promising new biomarkers for cancer screening is mutated DNA released from tumor cells into the bloodstream. Trials are currently ongoing evaluating this new biomarkers for a range of different cancer types.

Featured Image